VentriPoint Diagnostics Ltd

VentriPoint Diagnostics Ltd has a negative equity position of CAD -2,981,870 and a current ratio of 0.14, indicating significant liquidity constraints. The company's market capitalization is CAD 28,148,878.65, with a market price of CAD 0.15 per share. The enterprise value to revenue ratio is 312.32, suggesting a high valuation relative to its revenue of CAD 95,170. The company's profitability is challenged, with a net income of CAD -4,919,570 and an operating income of CAD -4,794,240. Return on equity is 1.65%, and return on assets is -7.48%, both significantly below industry norms for medical equipment firms. The gross profit equals the total revenue, indicating no cost of goods sold, which is unusual for a medical device company. VentriPoint Diagnostics Ltd's revenue is not segmented by geographic region or product line in the provided data. The company's primary focus is on diagnostic tools for heart disease, with a flagship product, the Ventripoint Medical System (VMS+), which is used for echocardiography and MRI software. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow is negative at CAD -3,386,200, and free cash flow is CAD -4,856,700, indicating ongoing cash burn. The company's net income has not improved from the previous year, and the last actual EPS was -1.20 CAD. The risk assessment indicates medium liquidity risk and low dilution risk. The company's key financial flag is negative net cash after subtracting total debt. The debt-to-equity ratio is -0.55, suggesting a complex capital structure with more liabilities than equity. Recent events include the continued development and commercialization of the VMS+ product, which is powered by proprietary Knowledge Based Reconstruction technology. The company has not disclosed any recent filings or transcripts that would indicate significant changes in its business strategy or financial position.